Could a common painkiller boost cancer treatment?
NCT ID NCT04188119
Summary
This study aimed to see if adding aspirin to an immunotherapy drug (avelumab) could improve the body's immune attack against triple-negative breast cancer, a difficult-to-treat type. It planned to enroll 42 patients who would receive the drug, with half also taking aspirin for about 18 days. Researchers would compare changes in the tumor and immune system using biopsies and blood tests before and after treatment. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.